Edition:
India

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

343.50DKK
20 Apr 2018
Change (% chg)

kr.-4.40 (-1.26%)
Prev Close
kr.347.90
Open
kr.347.00
Day's High
kr.347.00
Day's Low
kr.342.00
Volume
281,124
Avg. Vol
401,178
52-wk High
kr.413.20
52-wk Low
kr.280.80

Select another date:

Wed, Feb 7 2018

BRIEF-Lundbeck Says New CEO To Be Named Within Six Months

* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS

UPDATE 1-Lundbeck's Q4 operating profit falls short of expectations

COPENHAGEN, Feb 7 Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.

Lundbeck's Q4 operating profit below expectations

COPENHAGEN, Feb 7 Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Shares in Denmark's Lundbeck drop as sales of key drugs disappoint

COPENHAGEN, Nov 8 Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.

BRIEF-Lundbeck CEO sees U.S. prices to increase steadily

* INTERIM CEO SAYS EXPECTS U.S. PRICE INCREASES TO CONTINUE AT CURRENT LEVELS GOING FORWARD Further company coverage: (Reporting by Julie Astrid Thomsen)

BRIEF-Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln

* LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

Select another date: